Imatinib is a tyrosine kinase inhibitor widely used in the treatment of chronic myelogenous leukemia. Originally designed to target the chronic-myelogenous-leukemia-specific tyrosine kinase bcr ...

Of the compounds Nick sent me for testing, I identified CGP 57148B (also known as STI571, Gleevec, Glivec or imatinib mesylate) as the most effective at killing CML cells without harming normal ...

Scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance in cancer cells, driving more aggressive cancer growth. The team trialled a precision ...

Duke-NUS scientists investigated how an inherited genetic variation common among East Asians contributes to drug resistance ...

Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent ...

A new approach helps examine the proportion of cancerous and healthy stem cells in patients with chronic myeloid leukemia and how this influences treatment outcomes.

One of the most common treatments for chronic myeloid leukemia is a class of drugs known as tyrosine kinase inhibitors, with imatinib being one of the most widely used. However, patients with the BIM ...

Exactly three years after an initial FDA green light for the third-line treatment of leukemia, Novartis’ Scemblix has won an ...

More than 95% of chronic myeloid leukemia (CML) and 20%-30% of acute lymphoblastic leukemia (ALL) patients express the fusion ...

Find all the commercial and brand names of generic drug called Imatinib. This is an invaluable reference resource for healthcare professionals, patients, caregivers and anyone in need of ...

Jefferies initiated coverage of Inhibikase Therapeutics (IKT) with a Buy rating and $8 price target The stock looks inexpensive as its novel ...

Topline results from registration-directed trial of ziftomenib in R/R NPM1-mutant AML expected in early 2025; Phase 1 results published in The ...